Huddy JR, Ni MZ, Markar SR, Hanna GB. Point-of-care testing in the diagnosis of gastrointestinal cancers: Current technology and future directions. World J Gastroenterol 2015; 21(14): 4111-4120 [PMID: 25892860 DOI: 10.3748/wjg.v21.i14.4111]
Corresponding Author of This Article
George B Hanna, PhD, FRCS, Professor, Head, Department of Surgery and Cancer, Imperial College London, St Mary’s Hospital, Academic Surgical Unit, 10th Floor, QEQM Building, South Wharf Road, W2 1NY London, United Kingdom. g.hanna@imperial.ac.uk
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Apr 14, 2015; 21(14): 4111-4120 Published online Apr 14, 2015. doi: 10.3748/wjg.v21.i14.4111
Point-of-care testing in the diagnosis of gastrointestinal cancers: Current technology and future directions
Jeremy R Huddy, Melody Z Ni, Sheraz R Markar, George B Hanna
Jeremy R Huddy, Melody Z Ni, Sheraz R Markar, George B Hanna, Department of Surgery and Cancer, Imperial College London, St Mary’s Hospital, South Wharf Road, W2 1NY London, United Kingdom
Author contributions: Hanna GB conceptualized the paper; Huddy JR conducted the literature search; all authors were involved in the manuscript development and its revision; all authors read and approved the final manuscript.
Supported by NIHR Diagnostic Evidence Co-operative London at Imperial College Healthcare NHS Trust is funded by the National Institute for Health Research.
Conflict-of-interest: The authors declare no conflicts-of-interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: George B Hanna, PhD, FRCS, Professor, Head, Department of Surgery and Cancer, Imperial College London, St Mary’s Hospital, Academic Surgical Unit, 10th Floor, QEQM Building, South Wharf Road, W2 1NY London, United Kingdom. g.hanna@imperial.ac.uk
Telephone: +44-207-8862124 Fax: +44-207-8866309
Received: December 17, 2014 Peer-review started: December 18, 2014 First decision: January 8, 2015 Revised: January 20, 2015 Accepted: February 13, 2015 Article in press: February 13, 2015 Published online: April 14, 2015 Processing time: 118 Days and 13.6 Hours
Core Tip
Core tip: Point-of-care tests are well established. They facilitate real time clinical decision-making and can be cost-effective, reduce in-patient hospital stay and increase patient satisfaction. Faecal Occult Blood has been used internationally since 1993 in screening for colorectal cancer. Six technologies for current or potential point-of-care diagnosis of gastro-intestinal cancer were identified from the literature (faecal occult blood, faecal proteins, volatile organic compounds, pyruvate kinase isoenzyme type M2, tumour markers and DNA analysis). Currently, three have commercially available point-of-care devices. New technologies demonstrate potential to provide accuracy and an ability to diagnose gastrointestinal cancer earlier leading to improved clinical outcome and survival.
